SIRT clinical trial Australia and several European countries

CIS-GEM Chemotherapy+/- SIRT as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)
https://clinicaltrials.gov/ct2/show/NCT02807181

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)

The new ESMO guidelines on biliary cancers were published in September 2016 as a supplement to the Annals of Oncology.1 Their lead author, Professor Juan Valle, department of medical oncology, Christie NHS Foundation Trust, University of Manchester, UK, states that selective internal radiation therapy (SIRT), which is also known as radioembolisation, “may be considered in patients with inoperable iCCA, usually after first-line chemotherapy.”

The SIRT in Cholangiocarcinoma (SIRCCA) study is examining the role of SIR-Spheres Y-90 resin microspheres followed by the standard-of-care first-line chemotherapy for iCCA, compared to chemotherapy alone.

Click on below link for locations:
https://clinicaltrials.gov/ct2/show/study/NCT02807181#contacts